Penn Medicine Abramson Cancer Center


 

Penn Update on Novel Therapies for Higher Risk MDS: What Is the Role of Pevonedistat & Sabatolimab? Is Venetoclax an Option? Should We Consider Magrolimab? Is Enasidenib Effective in IDH2 MDS?

0 views
March 2, 2021
Comments 0
Login to view comments. Click here to Login